Skip to main content
Fig. 1 | Trials

Fig. 1

From: An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

Fig. 1

ILiAD trial outline. The ILiAD trial is a double-blind, placebo-controlled crossover study with study visits each month. It is a designed to provide pilot data to determine whether there may be a role for levetiracetam, an anti-seizure medication, in helping memory problems in people with Alzheimer’s disease (EEG = electroencephalogram; MoCA = Montreal Cognitive Assessment)

Back to article page

Trials

ISSN: 1745-6215